BioInfra Past Earnings Performance

Past criteria checks 0/6

BioInfra's earnings have been declining at an average annual rate of -87.1%, while the Life Sciences industry saw earnings declining at 3.1% annually. Revenues have been declining at an average rate of 9.6% per year.

Key information

-87.07%

Earnings growth rate

-87.20%

EPS growth rate

Life Sciences Industry Growth	53.72%
Revenue growth rate	-9.65%
Return on equity	-78.85%
Net Margin	-42.60%
Last Earnings Update	31 Mar 2026

Recent past performance updates

No updates

Recent updates

Analysis Article • Jan 08

BioInfra Co., Ltd.'s (KOSDAQ:199730) Share Price Is Matching Sentiment Around Its Revenues

With a price-to-sales (or "P/S") ratio of 1.2x BioInfra Co., Ltd. ( KOSDAQ:199730 ) may be sending very bullish signals...

Revenue & Expenses Breakdown

How BioInfra makes and spends money. Based on latest reported earnings, on an LTM basis.

Earnings and Revenue History

KOSDAQ:A199730 Revenue, expenses and earnings (KRW Millions)
Date	Revenue	Earnings	G+A Expenses	R&D Expenses
31 Mar 26	23,207	-9,887	2,943	8,184
31 Dec 25	23,148	-9,131	2,857	8,010
30 Sep 25	21,923	-5,628	2,788	7,952
30 Jun 25	24,475	-4,604	2,942	7,312
31 Mar 25	24,252	-4,236	2,958	7,314
31 Dec 24	23,833	-3,976	3,087	6,960
30 Sep 24	26,147	-2,376	3,052	6,156
30 Jun 24	26,357	-771	2,979	5,567
31 Mar 24	29,027	1,186	3,073	4,924
31 Dec 23	30,129	2,002	3,133	4,488
30 Sep 23	28,543	1,315	3,407	4,489
30 Jun 23	27,619	1,943	3,184	4,647
31 Mar 23	29,263	3,199	3,235	4,128
31 Dec 22	35,427	6,237	3,022	4,006
30 Sep 22	37,820	6,610	2,749	3,822
30 Jun 22	39,430	7,223	2,704	3,220
31 Mar 22	36,051	6,924	2,053	3,170
31 Dec 21	30,555	6,234	1,406	2,781
31 Dec 20	19,610	4,191	1,543	2,777
31 Dec 19	17,290	-2,626	2,151	2,506
31 Dec 16	5,816	411	844	0
31 Dec 15	6,364	294	969	0

Quality Earnings: A199730 is currently unprofitable.

Growing Profit Margin: A199730 is currently unprofitable.

Free Cash Flow vs Earnings Analysis

Past Earnings Growth Analysis

Earnings Trend: A199730 is unprofitable, and losses have increased over the past 5 years at a rate of 87.1% per year.

Accelerating Growth: Unable to compare A199730's earnings growth over the past year to its 5-year average as it is currently unprofitable

Earnings vs Industry: A199730 is unprofitable, making it difficult to compare its past year earnings growth to the Life Sciences industry (-26.7%).

Return on Equity

High ROE: A199730 has a negative Return on Equity (-78.85%), as it is currently unprofitable.

Return on Assets

Return on Capital Employed

Discover strong past performing companies

Company Analysis and Financial Data Status

Data	Last Updated (UTC time)
Company Analysis	2026/07/06 08:47
End of Day Share Price	2026/07/06 00:00
Earnings	2026/03/31
Annual Earnings	2025/12/31

Data Sources

The data used in our company analysis is from S&P Global Market Intelligence LLC. The following data is used in our analysis model to generate this report. Data is normalised which can introduce a delay from the source being available.

Package	Data	Timeframe	Example US Source ^*
Company Financials	10 years	Income statement Cash flow statement Balance sheet	SEC Form 10-K SEC Form 10-Q
Analyst Consensus Estimates	+3 years	Forecast financials Analyst price targets	Analyst Research Reports Blue Matrix
Market Prices	30 years	Stock prices Dividends, Splits and Actions	ICE Market Data SEC Form S-1
Ownership	10 years	Top shareholders Insider trading	SEC Form 4 SEC Form 13D
Management	10 years	Leadership team Board of directors	SEC Form 10-K SEC Form DEF 14A
Key Developments	10 years	Company announcements	SEC Form 8-K

^* Example for US securities, for non-US equivalent regulatory forms and sources are used.

Unless specified all financial data is based on a yearly period but updated quarterly. This is known as Trailing Twelve Month (TTM) or Last Twelve Month (LTM) Data. Learn more.

Analysis Model and Snowflake

Details of the analysis model used to generate this report is available on our Github page, we also have guides on how to use our reports and tutorials on Youtube.

Learn about the world class team who designed and built the Simply Wall St analysis model.

Industry and Sector Metrics

Our industry and section metrics are calculated every 6 hours by Simply Wall St, details of our process are available on Github.

Analyst Sources

BioInfra Co., Ltd. is covered by 0 analysts. 0 of those analysts submitted the estimates of revenue or earnings used as inputs to our report. Analysts submissions are updated throughout the day.